Remove 2007 Remove FDA Approval Remove Pharmaceuticals
article thumbnail

Gepirone

New Drug Approvals

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] The FDA rejected approval for gepirone in 2002 and 2004. [5] 1] It is taken orally.

FDA 62
article thumbnail

Inavolisib

New Drug Approvals

3] Inavolisib was approved for medical use in the United States in October 2024. [3] 1, 2007, 41-44) (2.30 19] Society and culture Legal status In October 2024, the US Food and Drug Administration (FDA) approved inavolisib for the treatment of PIK3CA -mutant breast cancer based on the results from the INAVO120 trial. [3]

FDA 57
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia. We treated our first patient with CD19 CAR T cells back in 2007. That boosting signal is a staple of all CARs used today.

Therapies 119
article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Currently, three FDA-approved disease-modifying drug therapies are available: hydroxyurea, crizanlizumab and L-glutamine, though each has limitations that affect patient compliance. The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease. JAMA Netw Open. 2023 Nov 1;6(11):e2344546.

Disease 52
article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

Salt Formation: The pritelivir free base is then reacted with methanesulfonic acid to form the mesylate salt, which is the active pharmaceutical ingredient (API). 7] If the virus also acquires resistance to foscarnet, then there is currently no FDA approved treatment. 316 (23): 2495–2503. doi : 10.1001/jama.2016.18189.

Virus 62
article thumbnail

Landiolol

New Drug Approvals

Landiolol 133242-30-5 ONO-1101 Ono 1101 WHO 7516 FDA APPROVED 11/22/2024, Rapiblyk , To treat supraventricular tachycardia C25H39N3O8 509.6 Landiolol was approved for medical use in Japan in 2002, [10] [11] in Canada in November 2023, [1] and in the United States in November 2024. [12] Food and Drug Administration (FDA).

FDA 62
article thumbnail

Seladelpar

New Drug Approvals

4] Seladelpar was approved for medical use in the United States in August 2024. [1] 2007 Jul 15;17(14):3855-9. Epub 2007 May 10. 2007.05.007 Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, LLC, 8 Clarke Drive, Cranbury, NJ 08512, USA Scheme 1. 1] It is used as the lysine dihydrate salt. [1]

FDA 62